# US 2024/0391970 A1 · Compositions and methods for treatment of fungal infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391970 A1
- Document ID: US20240391970A1
- Status: Published application
- Kind: A1
- Application number: 18/670,613
- Filed: 2024-05-21
- Published: 2024-11-28
- Earliest claimed: 2020-06-26
- Assignees: University of Southern California
- Applicants: The University of Southern California
- Inventors: Michael E. Selsted; Dat Q. Tran; Justin B. Schaal; Virginia Basso
- Web page: https://patentgrep.com/patent/US20240391970A1

## CPC

- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- A61P 31/10: Antimycotics
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Peptide analogs of a θ-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensins.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of treating or preventing disseminated fungal infection and associated septic shock, comprising:
identifying an individual in need of treatment for disseminated fungal infection; and
administering a cyclic peptide of an animal at risk of septic shock, wherein the cyclic
peptide has the following structure:
wherein AA3 and AA12 are cysteines joined by a disulfide bond, AA5 and AA10 are cysteines joined by a disulfide bond, AA4 is arginine, AA11 is arginine, two of AA6, AA7, and AA8 are arginine, wherein a β turn segment of the cyclic peptide defined by AA6, AA7, AA8, and AA9 does not include more than two adjacent arginines, and wherein the cyclic peptide comprises five or more arginine residues that provide a positively charged content of at least about 36% at physiological pH.

### Claim 12 (depends on 11)

The method of claim 11, wherein AA1 is glycine.

### Claim 13 (depends on 11)

The method of claim 11, wherein at least one of AA2 and AA9 is a hydrophobic amino acid.

### Claim 14 (depends on 11)

The method of claim 11, wherein at least one of AA13 and AA14 is arginine.

### Claim 15 (depends on 11)

The method of claim 11, wherein the cyclic peptide is an analog of a θ-defensin, and wherein the cyclic peptide provides improved survival when applied systemically in a murine model of disseminated candidiasis relative to the θ-defensin.

### Claim 16 (depends on 11)

The method of claim 11, wherein the method provides a biphasic response on application to a murine model of disseminated candidiasis, wherein the biphasic response comprises a first phase of mobilization of host effector cells having antifungal activity and a second phase of moderation of host inflammatory response.

### Claim 17 (depends on 11)

The method of claim 11, wherein the method inhibits TACE activity.

### Claim 18 (depends on 11)

The method of claim 11, wherein the method suppresses at least one of expression, processing, and release of a proinflammatory cytokine.

### Claim 19 (depends on 11)

The method of claim 11, wherein the method activates a host immune system to enhance host clearance of pathogens.
